Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12623000862640
ACTRN12623000862640
Not yet recruiting
未知

Assessment of the feasibility, safety, tolerability and efficacy of dulaglutide, a glucagon-like peptide-1 receptor agonist in dialysis patients

Auckland City Hospital0 sites95 target enrollmentAugust 11, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEnd stage kidney diseaseDiabetesRenal and Urogenital - Kidney diseaseMetabolic and Endocrine - Diabetes

Overview

Phase
未知
Intervention
Not specified
Conditions
End stage kidney disease
Sponsor
Auckland City Hospital
Enrollment
95
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 11, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Type 2 diabetes.
  • •2\.Stable on either haemodialysis, peritoneal dialysis or hybrid therapy (both haemodialysis and peritoneal dialysis) for at least 3 months.
  • •3\.Aged 18 years old or older
  • •4\.Able to give informed consent.
  • •5\.HbA1c \>53mmol/mol

Exclusion Criteria

  • •Exclusion criteria
  • •1\.Known allergy or adverse drug effect to GLP\-1 receptor agonists
  • •2\.Known severe hepatic dysfunction such as portal hypertension or cirrhosis, acute or chronic hepatitis, signs or symptoms of other liver disease, or an alanine transaminase (ALT) level \>3 times the upper limit of normal
  • •3\.Have a past history of acute, chronic or idiopathic pancreatitis
  • •4\.Excessive alcohol intake above recommended levels
  • •5\.Type 1 diabetes
  • •6\.Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B
  • •7\.Malnutrition
  • •8\.Pregnancy
  • •9\.Planning for coronary, carotid or peripheral artery revascularisation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
Transplantation and Diabetes (Transdiab): A Pilot Randomised Controlled Trial of Metformin in pre-diabetes after kidney transplantatioew onset diabetes after kidney transplantatonNew onset diabetes after kidney transplantatonRenal and Urogenital - Kidney diseaseMetabolic and Endocrine - Diabetes
ACTRN12614001171606Auckland District Health Board200
Recruiting
Phase 1
Treatment Resistant Depression Intervention with Psilocybin-assisted PsychotherapyTreatment Resistant DepressionMental Health - Depression
ACTRN12623000832673St. Vincent's Hospital, Sydney20
Completed
Not Applicable
To explore safety and feasibility of mobile teledermoscopy for Queensland residents 50-64 year of age at high risk for melanoma.Skin CancerMelanomaSkin CancerMelanomaCancer - Malignant melanoma
ACTRN12613000590763Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI)50
Recruiting
Not Applicable
Safety and efficacy of biodegradable biliary and pancreatic stentsBiliary anastomotic strictureHepatico-jejunal stricturePost-ERCP pancreatitisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
ACTRN12621001534875Royal Prince Alfred Hospital60
Active, not recruiting
Phase 1
Evaluation of safety, feasibility and preliminary efficacy of MSCs from third party donors in the treatment of patients with osteonecrosis of the femoral head after allogeneic Stem Cell Transplantatio
EUCTR2018-000886-35-ESEnrique Gomez-Barrena7